Molecular testing panel in colorectal cancer

Yi Ding; Guoli Chen

doi:10.1016/j.hpr.2022.300632

Molecular testing panel in colorectal cancer

Yi Ding, Guoli Chen

Department of Pathology and Laboratory Medicine

Research output: Contribution to journal › Review article › peer-review

Abstract

Mainly driven by the clinical need, molecular genetic testing has been integrated into the standard patient care of cancer management including colorectal cancer (CRC) for various clinical purposes. A proper selection of anti-cancer therapies relies on information achieved by molecular genetic analysis. Also, molecular findings are often necessary or helpful in screening, diagnosis and prognosis of CRC and related diseases/syndromes. New molecular classification may profoundly alter the current understanding and clinical management of CRC. As a powerful sequencing tool, next generation sequencing has become the main platform of conducting cancer related molecular diagnostic tests. In this review, molecular biomarkers widely used in the current practice of CRC management are briefly discussed according to their clinical significance.

Original language	English (US)
Article number	300632
Journal	Human Pathology Reports
Volume	28
DOIs	https://doi.org/10.1016/j.hpr.2022.300632
State	Published - Jun 2022

All Science Journal Classification (ASJC) codes

Pathology and Forensic Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.hpr.2022.300632

Cite this

@article{a162e33d2c1e4d0eaa2b36ca1324677b,

title = "Molecular testing panel in colorectal cancer",

abstract = "Mainly driven by the clinical need, molecular genetic testing has been integrated into the standard patient care of cancer management including colorectal cancer (CRC) for various clinical purposes. A proper selection of anti-cancer therapies relies on information achieved by molecular genetic analysis. Also, molecular findings are often necessary or helpful in screening, diagnosis and prognosis of CRC and related diseases/syndromes. New molecular classification may profoundly alter the current understanding and clinical management of CRC. As a powerful sequencing tool, next generation sequencing has become the main platform of conducting cancer related molecular diagnostic tests. In this review, molecular biomarkers widely used in the current practice of CRC management are briefly discussed according to their clinical significance.",

author = "Yi Ding and Guoli Chen",

note = "Publisher Copyright: {\textcopyright} 2022",

year = "2022",

month = jun,

doi = "10.1016/j.hpr.2022.300632",

language = "English (US)",

volume = "28",

journal = "Human Pathology Reports",

issn = "2772-736X",

publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Molecular testing panel in colorectal cancer

AU - Ding, Yi

AU - Chen, Guoli

PY - 2022/6

Y1 - 2022/6

N2 - Mainly driven by the clinical need, molecular genetic testing has been integrated into the standard patient care of cancer management including colorectal cancer (CRC) for various clinical purposes. A proper selection of anti-cancer therapies relies on information achieved by molecular genetic analysis. Also, molecular findings are often necessary or helpful in screening, diagnosis and prognosis of CRC and related diseases/syndromes. New molecular classification may profoundly alter the current understanding and clinical management of CRC. As a powerful sequencing tool, next generation sequencing has become the main platform of conducting cancer related molecular diagnostic tests. In this review, molecular biomarkers widely used in the current practice of CRC management are briefly discussed according to their clinical significance.

AB - Mainly driven by the clinical need, molecular genetic testing has been integrated into the standard patient care of cancer management including colorectal cancer (CRC) for various clinical purposes. A proper selection of anti-cancer therapies relies on information achieved by molecular genetic analysis. Also, molecular findings are often necessary or helpful in screening, diagnosis and prognosis of CRC and related diseases/syndromes. New molecular classification may profoundly alter the current understanding and clinical management of CRC. As a powerful sequencing tool, next generation sequencing has become the main platform of conducting cancer related molecular diagnostic tests. In this review, molecular biomarkers widely used in the current practice of CRC management are briefly discussed according to their clinical significance.

UR - http://www.scopus.com/inward/record.url?scp=85128855201&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85128855201&partnerID=8YFLogxK

U2 - 10.1016/j.hpr.2022.300632

DO - 10.1016/j.hpr.2022.300632

M3 - Review article

AN - SCOPUS:85128855201

SN - 2772-736X

VL - 28

JO - Human Pathology Reports

JF - Human Pathology Reports

M1 - 300632

ER -

Molecular testing panel in colorectal cancer

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this